AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24929133 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component integrated control strategy including bovine vaccination using a heterologous 'prime-boost' delivery platform based on the SjCTPI vaccine.
Number of subjects: 0
Study 24929133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass human chemotherapy and mollusciciding as part of the integrated strategy.
Number of subjects: 0
Study 19826284 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallow on the rings
Number of subjects: 6
Study 19826284 — intervention group
Group type: COMPARATOR
Intervention: Counterweight exercise
Number of subjects: 6
Study 19826284 — intervention group
Group type: COMPARATOR
Intervention: Dumbbells exercise
Number of subjects: 6
Study 19826284 — intervention group
Group type: COMPARATOR
Intervention: Barbell exercise
Number of subjects: 6
Study 15076797 — intervention group
Group type: EXPERIMENTAL
Intervention: TriTrac-R3D monitors (TTM)
Number of subjects: 54
Study 15076797 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported activity measures
Number of subjects: 54
Study 15076797 — intervention group
Group type: COMPARATOR
Intervention: TTM
Number of subjects: 54
Study 11722852 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard information plus group and repeated individual information (n=70)
Number of subjects: 210
Study 11722852 — intervention group
Group type: COMPARATOR
Intervention: Standard information plus brochure (n=70)
Number of subjects: 210
Study 11722852 — intervention group
Group type: COMPARATOR
Intervention: Standard information only (n=70)
Number of subjects: 210
Study 9491040 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl, 15 to 20 microgram/kg
Number of subjects: 21
Study 9491040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7887105 — intervention group
Group type: EXPERIMENTAL
Intervention: GA combined with epidural anaesthesia (GA+EPI)
Number of subjects: 16
Study 7887105 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 16
Study 7887105 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (EPI)
Number of subjects: 16
Study 2964844 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-(1-21)-peptide
Number of subjects: 145
Study 2964844 — intervention group
Group type: COMPARATOR
Intervention: Glucagon
Number of subjects: 145
Study 2964844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 11240090 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil infusion
Number of subjects: 12
Study 11240090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 12
Study 11240090 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diphenhydramine)
Number of subjects: 12
Study 31055640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 68
Study 31055640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30180236 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine mouthwash
Number of subjects: 140
Study 30180236 — intervention group
Group type: EXPERIMENTAL
Intervention: D-panthenol gel
Number of subjects: 140
Study 30180236 — intervention group
Group type: EXPERIMENTAL
Intervention: D-panthenol mouthwash
Number of subjects: 140
Study 30180236 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Number of subjects: 140
Study 30180236 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of corn oil gel (placebo)
Number of subjects: 140
Study 30180236 — intervention group
Group type: EXPERIMENTAL
Intervention: Triester glycerol oxide gel
Number of subjects: 140
Study 30180236 — intervention group
Group type: COMPARATOR
Intervention: Denture grinding (control)
Number of subjects: 140
Study 27627073 — intervention group
Group type: EXPERIMENTAL
Intervention: GADA positive (GADA+) patients
Number of subjects: 625
Study 27627073 — intervention group
Group type: COMPARATOR
Intervention: GADA negative (GADA-) patients
Number of subjects: 625
Study 27627073 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for GADA and C-peptide levels
Number of subjects: 625
Study 24842806 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ovarian suspension
Number of subjects: 80
Study 24842806 — intervention group
Group type: COMPARATOR
Intervention: Control group (ovaries left free in the pelvis)
Number of subjects: 80
Study 24842806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 22687788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate (SSRI)
Number of subjects: 19
Study 22687788 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 19
Study 20091113 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 152
Study 20091113 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 152
Study 20091113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 17566094 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 0
Study 16060401 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg gabapentin (100 mg, twice daily)
Number of subjects: 61
Study 16060401 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg gabapentin (100 mg, four times daily)
Number of subjects: 61
Study 16060401 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg gabapentin (200 mg, three times daily)
Number of subjects: 61
Study 16060401 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study 12192247 — intervention group
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Number of subjects: 0
Study 12192247 — intervention group
Group type: EXPERIMENTAL
Intervention: anti‐BLyS monoclonal antibody
Number of subjects: 0
Study 12192247 — intervention group
Group type: EXPERIMENTAL
Intervention: anti‐CD40L monoclonal antibody
Number of subjects: 0
Study 12192247 — intervention group
Group type: EXPERIMENTAL
Intervention: immunoablation techniques
Number of subjects: 0
Study 10526722 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 165
Study 10526722 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 165
Study 7477802 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive-behavioral, nutritional and antidepressant therapy (5 with amineptine and 10 with fluvoxamine)
Number of subjects: 15
Study 1800693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentures constructed on free plane articulators
Number of subjects: 7
Study 1800693 — intervention group
Group type: COMPARATOR
Intervention: Dentures constructed on hinge articulators
Number of subjects: 7
Study 7036932 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate (single oral dose)
Number of subjects: 93
Study 7036932 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 93
Study 31480678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment (CBT) with development-specific topics for adolescents and young adults (YOUTH)
Number of subjects: 266
Study 31480678 — intervention group
Group type: COMPARATOR
Intervention: Age-unspecific CBT group intervention
Number of subjects: 266
Study 27783275 — intervention group
Group type: EXPERIMENTAL
Intervention: BLR 250, BLR 350 (new peritoneal dialysis fluids)
Number of subjects: 211
Study 27783275 — intervention group
Group type: COMPARATOR
Intervention: PD-4, PD-2 (standard peritoneal dialysis fluids)
Number of subjects: 211
Study 25677397 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with fluoxetine 20-40 mg/day plus interpersonal psychotherapy adapted to BPD (IPT-BPD) for 32 weeks
Number of subjects: 27
Study 25677397 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with fluoxetine 20-40 mg/day plus IPT-BPD
Number of subjects: 27
Study 24322997 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation
Number of subjects: 32
Study 24322997 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 21679182 — intervention group
Group type: EXPERIMENTAL
Intervention: High PCO2 solution
Number of subjects: 20
Study 21679182 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 N HCl solution (acid perfusion)
Number of subjects: 20
Study 21679182 — intervention group
Group type: COMPARATOR
Intervention: Comparison between NERD and healthy controls
Number of subjects: 20
Study 19358119 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative oral and nasal steroid therapy
Number of subjects: 63
Study 19358119 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (historical control)
Number of subjects: 63
Study 17953808 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12, folic acid, L-carnitine, and betaine supplementation
Number of subjects: 57
Study 17953808 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MMA with homocysteinemia
Number of subjects: 57
Study 15359637 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (involved fields, 40 Gy)
Number of subjects: 341
Study 15359637 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (control group)
Number of subjects: 341
Study 12363058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 351
Study 12363058 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 351
Study 12363058 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministered AQ+SP
Number of subjects: 351
Study 9723820 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 8
Study 9723820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8123489 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U of recombinant interleukin 2 (IL‐2)
Number of subjects: 31
Study 8123489 — intervention group
Group type: COMPARATOR
Intervention: 500,000 U of recombinant interleukin 2 (IL‐2)
Number of subjects: 31
Study 2678805 — intervention group
Group type: EXPERIMENTAL
Intervention: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 600 mg
Number of subjects: 30
Study 2678805 — intervention group
Group type: EXPERIMENTAL
Intervention: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 900 mg
Number of subjects: 30
Study 2678805 — intervention group
Group type: EXPERIMENTAL
Intervention: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 1200 mg
Number of subjects: 30
Study 2678805 — intervention group
Group type: EXPERIMENTAL
Intervention: 0‐(beta‐Hydroxylethyl)‐rutoside (HR) drinking solutions at 1500 mg
Number of subjects: 30
Study 2678805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1170119 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 0.05 μ/kg body weight injected intravenously at 8 a.m.
Number of subjects: 14
Study 1170119 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 0.05 μ/kg body weight injected intravenously at 5 p.m.
Number of subjects: 14
Study 1170119 — intervention group
Group type: COMPARATOR
Intervention: Insulin injection in the afternoon vs morning
Number of subjects: 14
Study 1170119 — intervention group
Group type: COMPARATOR
Intervention: Caloric change in plasma after insulin injection
Number of subjects: 14
Study 1170119 — intervention group
Group type: COMPARATOR
Intervention: Plasma growth hormone response
Number of subjects: 14
Study 31809392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored PriCARE
Number of subjects: 150
Study 31809392 — intervention group
Group type: EXPERIMENTAL
Intervention: PriCARE
Number of subjects: 150
Study 31809392 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 30555044 — intervention group
Group type: EXPERIMENTAL
Intervention: Small colorectal polyps with at least one cancer associated event (CAE)
Number of subjects: 68
Study 30555044 — intervention group
Group type: EXPERIMENTAL
Intervention: Small colorectal polyps with ≥2 mutations
Number of subjects: 68
Study 30555044 — intervention group
Group type: EXPERIMENTAL
Intervention: Small colorectal polyps that regressed
Number of subjects: 68
Study 30555044 — intervention group
Group type: EXPERIMENTAL
Intervention: All samples analyzed for MMR proficiency
Number of subjects: 68
Study 30555044 — intervention group
Group type: EXPERIMENTAL
Intervention: Small colorectal polyps with CIMP analysis
Number of subjects: 68
Study 28331291 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-8031 at doses of 5, 10, 20, 40, 60, 80, or 120 mg
Number of subjects: 0
Study 28331291 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-8031 (80 mg or less)
Number of subjects: 0
Study 28331291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26385201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis (12.5% tetrahydrocannabinol), median daily dose of 2.5 g/d
Number of subjects: 431
Study 26385201 — intervention group
Group type: COMPARATOR
Intervention: Control (no cannabis use)
Number of subjects: 431
Study 26385201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis
Number of subjects: 431
Study 22790513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (Avastin) with Ahmed valve implantation and panretinal photocoagulation (PRP)
Number of subjects: 40
Study 22790513 — intervention group
Group type: COMPARATOR
Intervention: Ahmed valve implantation with panretinal photocoagulation (PRP) (control group)
Number of subjects: 40
Study 22046230 — intervention group
Group type: COMPARATOR
Intervention: Informed consent comprehension quiz administered at enrollment and during follow-up
Number of subjects: 1835
Study 18164467 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 0
Study 18164467 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0
Study 18164467 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 17123192 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate training (IT) for new HA users; 8 weeks of at-home syllable identification training and in-laboratory testing.
Number of subjects: 0
Study 17123192 — intervention group
Group type: COMPARATOR
Intervention: Delayed training (DT) for new HA users; identical in-laboratory testing without training initially, followed by training after initial testing.
Number of subjects: 0
Study 17123192 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for experienced HA users; identical training and testing procedures as new HA users.
Number of subjects: 0
Study 17123192 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-related improvements for both new and experienced HA users.
Number of subjects: 0
Study 14580826 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading in an orthosis
Number of subjects: 28
Study 14580826 — intervention group
Group type: COMPARATOR
Intervention: Traditional serial plaster casting
Number of subjects: 28
Study 11053903 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 300 mg/24 h
Number of subjects: 3
Study 11053903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg/12 h
Number of subjects: 3
Study 11053903 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 300 mg/24 h plus cefepime 2 g/12 h
Number of subjects: 3
Study 11053903 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg/12 h plus cefepime 2 g/12 h
Number of subjects: 3
Study 11053903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimens (both)
Number of subjects: 3
Study 9253781 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard packed red blood cell (RBC) transfusions
Number of subjects: 0
Study 9253781 — intervention group
Group type: COMPARATOR
Intervention: Leukocyte-depleted red blood cell (RBC) transfusions
Number of subjects: 0
Study 8290662 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance antidepressants
Number of subjects: 300
Study 8290662 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment
Number of subjects: 300
Study 3944373 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate aerosol (1050 micrograms)
Number of subjects: 12
Study 3944373 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol (255 micrograms)
Number of subjects: 12
Study 3944373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31439640 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐chloroprocaine
Number of subjects: 150
Study 31439640 — intervention group
Group type: COMPARATOR
Intervention: prilocaine
Number of subjects: 150
Study 28192588 — intervention group
Group type: EXPERIMENTAL
Intervention: 70° side-cut
Number of subjects: 29
Study 28192588 — intervention group
Group type: COMPARATOR
Intervention: 115° side-cut
Number of subjects: 29
Study 28192588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (70° and 115° side-cuts)
Number of subjects: 29
Study 26068110 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycaemic control
Number of subjects: 41
Study 26068110 — intervention group
Group type: COMPARATOR
Intervention: Exogenous insulin delivery
Number of subjects: 41
Study 24411753 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week behavioral weight loss intervention
Number of subjects: 132
Study 23199586 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurazone-impregnated silicone catheter
Number of subjects: 7102
Study 23199586 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver alloy-coated hydrogel latex catheter
Number of subjects: 7102
Study 23199586 — intervention group
Group type: COMPARATOR
Intervention: PTFE-coated latex catheter
Number of subjects: 7102
Study 18983947 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-84) for 18 months
Number of subjects: 23
Study 18983947 — intervention group
Group type: EXPERIMENTAL
Intervention: PTH(1-84) for 24 months
Number of subjects: 23
Study 18983947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17526462 — intervention group
Group type: EXPERIMENTAL
Intervention: tobramycin 0.3%/dexamethasone 0.1%
Number of subjects: 40
Study 17526462 — intervention group
Group type: COMPARATOR
Intervention: tobramycin 0.3%/loteprednol 0.5%
Number of subjects: 40
Study 14620389 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 5 microg/kg given once/day
Number of subjects: 222
Study 10852359 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressed desire for treatment
Number of subjects: 823
Study 10852359 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility for methadone maintenance
Number of subjects: 823
Study 10852359 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more previous treatment admissions
Number of subjects: 823
Study 10852359 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of injection
Number of subjects: 823
Study 10852359 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin use in the past 30 days
Number of subjects: 823
Study 10852359 — intervention group
Group type: EXPERIMENTAL
Intervention: Being HIV positive
Number of subjects: 823
Study 10852359 — intervention group
Group type: EXPERIMENTAL
Intervention: Giving money or drugs for sex
Number of subjects: 823
Study 10852359 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of injection-related risk for HIV infection
Number of subjects: 823
Study 8614420 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiation therapy
Number of subjects: 244
Study 8614420 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy followed by chemotherapy
Number of subjects: 244
Study 1477397 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity at work
Number of subjects: 577
Study 1477397 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure time physical activities
Number of subjects: 577
Study 6383269 — intervention group
Group type: EXPERIMENTAL
Intervention: LYCD ointment
Number of subjects: 9
Study 6383269 — intervention group
Group type: COMPARATOR
Intervention: Ointment base (Control)
Number of subjects: 9
Study 2880362 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine (20.5 mg/day)
Number of subjects: 33
Study 2880362 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (5.5 mg/day)
Number of subjects: 33
Study 2880362 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (11 mg/day) + Biperiden (7 mg/day)
Number of subjects: 33
Study 2880362 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprothixene (142 mg/day)
Number of subjects: 33
Study 2880362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31743982 — intervention group
Group type: EXPERIMENTAL
Intervention: Technological proprioceptive rehabilitation (TG)
Number of subjects: 64
Study 31743982 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CG)
Number of subjects: 64
Study 28786323 — intervention group
Group type: COMPARATOR
Intervention: Advance care planning with family carers, including a trained facilitator, family education, family meetings, documentation of advance care planning decisions, and intervention orientation for general practitioners and nursing home staff.
Number of subjects: 24
Study 26104968 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR)
Number of subjects: 22
Study 26104968 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (HS)
Number of subjects: 22
Study 24714773 — intervention group
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Number of subjects: 245
Study 24714773 — intervention group
Group type: COMPARATOR
Intervention: Paracentesis alone
Number of subjects: 245
Study 23515883 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM)
Number of subjects: 233
Study 23515883 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-hospital visits
Number of subjects: 233
Study 20437350 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel hemostatic devices
Number of subjects: 195
Study 20437350 — intervention group
Group type: COMPARATOR
Intervention: Classic suture ligation technique
Number of subjects: 195
Study 18410803 — intervention group
Group type: EXPERIMENTAL
Intervention: Day cream with photostable combination of UVB and UVA filters
Number of subjects: 12
Study 16606638 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed brochure and electronic newsletters (print group)
Number of subjects: 963
Study 16606638 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio advertisements (radio group)
Number of subjects: 963